Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Non-Hodgkin lymphoma

A dramatic development in diagnostics for non-Hodgkin lymphoma (NHL) has occurred during the last 10-15 years. New advances in immunology and cytogenetics/DNA technology and especially immunophenotyping have provided better classification and more precise diagnosis, for the patient. 

NHL is separated into 25 subgroups of importance for treatment and prognosis. Histological types are more important for prognosis and choice of treatment than clinical stage (except for stage I). This is partly due to the fact that about 2 out of 3 patients have advanced disease (stages III or IV) and partly because chemotherapy plays a more important role than radiation therapy. 


Non-Hodgkin lymphoma is more common in men than women. In 2017, it is estimated to be 72,240 new cases of non-Hodgkin lymphoma in the United States. Non-Hodgkin lymphoma is most frequently diagnosed among people aged 65-74 and represents 4.3% of all new cancer cases in the United States.


Age-specific incidence of non-Hodgkin's Lymphoma, 2010–2014.

Source: National Cancer Institute. Bethesda, MD, USA



Incidence of non-Hodgkin's lymphoma, 1975–2014.

Source: National Cancer Institute. Bethesda, MD, USA

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2018